Xenikos aims to develop a new medicine, based on the action of toxin-conjugated antibodies that enables patients suffering serious immune diseases, or rejection after transplantation, to reset their immune system quickly and efficiently. Xenikos strives to develop new, innovative immunotherapy medicines to help restore patients’ health and save lives.

Latest news

18 december 2019

Xenikos announces first patient receives T-Guard® for steroid-refractory acute GVHD in pivotal U.S.-based Phase 3 trial

3 december 2019

Xenikos presents promising new data from expanded access program (EAP) using T-Guard® to treat steroid-refractory acute GVHD at ASH Annual Meeting

2 december 2019

Xenikos appoints Stanley Musial as Chief Financial Officer and Chief Business Officer

To all news

Introducing T-Guard®

T-Guard® is a medicine currently under development that safely and swiftly ‘resets’ the body’s immune system. It shows potential in the effective treatment of certain life-threatening immune conditions, such as transplant-related rejection, acute Graft versus Host Disease (aGVHD), solid-organ rejection and several severe autoimmune diseases.

A Patient’s Story

Jan Willem was diagnosed with a rare form of leukemia in 1994. His diagnosis was the start of a remarkable journey to recovery that demonstrates the potential of T-Guard® as a life-saving treatment option.

A Patient’s Story

Jan Willem was diagnosed with a rare form of leukemia in 1994. His diagnosis was the start of a remarkable journey to recovery that demonstrates the potential of T-Guard® as a life-saving treatment option.

Our investors